This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Follistatin
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict SKIP-FOR-NOW MEDIUM
Strong animal hypertrophy signal but failed clinical program (Acceleron ACE-031 cardiac/vascular safety halt, ACE-083 missed efficacy endpoints), thin healthy-adult human evidence, and peptide-vendor identity is questionable for a 30+ kDa glycoprotein that almost certainly cannot survive subQ injection intact. Verdict could shift if a gene-therapy trial demonstrates clean safety in healthy adults or if a credible non-glycosylated peptide mimetic emerges with proper COA chain.
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
★20-30, brain-priority, high cognitive workload (this-archetype) | SKIP-AT- | No brain benefit, theoretical cardiac risk during a developmental window, sourcing is identity-fraud territory, and goal of muscle is downstream priority #5 not #1. Free behavioral lever (training + protein + sleep) does most of what this allegedly does, with zero risk. |
30-50, executive maintenance | SKIP | Same risk/identity issues; no evidence of any benefit relevant to executive function or longevity. |
50+, mild cognitive decline | SKIP | for cognitive purposes (no relevance). For sarcopenia specifically, watch the gene-therapy + bimagrumab class — but currently no path. |
Anxiety-prone | SKIP | no anxiolytic profile, vascular side effects could spike anxiety. |
High athletic load, tested status | SKIP | WADA-banned (myostatin antagonists are S2 prohibited at all times). |
Sleep-disordered | N | applicable. |
Recovery-focused (post-injury, post-illness) | T | interesting for muscle wasting in cachexia/sarcopenia, but for a healthy 20yo recovering from MMA training load? Massively overkill and risk-mismatched. Skip. |
Strength/anabolic-focused | T | is the only profile where it's even tempting. Even here: failed clinical program + identity-fraud vendor market + cardiac hypertrophy theoretical = the strength-focused 25+yo lifter is better served by AAS or SARMs (worse but at least real and titratable) than by paying $200/vial for what is most likely saline + peptide impurity. |
- ★20-30, brain-priority, high cognitive workload (this-archetype)SKIP-AT-
No brain benefit, theoretical cardiac risk during a developmental window, sourcing is identity-fraud territory, and goal of muscle is downstream priority #5 not #1. Free behavioral lever (training + protein + sleep) does most of what this allegedly does, with zero risk.
- 30-50, executive maintenanceSKIP
Same risk/identity issues; no evidence of any benefit relevant to executive function or longevity.
- 50+, mild cognitive declineSKIP
for cognitive purposes (no relevance). For sarcopenia specifically, watch the gene-therapy + bimagrumab class — but currently no path.
- Anxiety-proneSKIP
no anxiolytic profile, vascular side effects could spike anxiety.
- High athletic load, tested statusSKIP
WADA-banned (myostatin antagonists are S2 prohibited at all times).
- Sleep-disorderedN
applicable.
- Recovery-focused (post-injury, post-illness)T
interesting for muscle wasting in cachexia/sarcopenia, but for a healthy 20yo recovering from MMA training load? Massively overkill and risk-mismatched. Skip.
- Strength/anabolic-focusedT
is the only profile where it's even tempting. Even here: failed clinical program + identity-fraud vendor market + cardiac hypertrophy theoretical = the strength-focused 25+yo lifter is better served by AAS or SARMs (worse but at least real and titratable) than by paying $200/vial for what is most likely saline + peptide impurity.
▸ Subjective experience (deep)
For vendor-sourced "follistatin" peptide: Users report nothing acute (no stim, no flush, no sleep effect) and claim slow lean-mass gains over 4-6 weeks. Indistinguishable from placebo + concurrent training adjustment. No reliable subjective marker. This is a flag that either (a) it's not bioactive, or (b) it's so subtle the placebo response dominates.
For ACE-031 trial subjects: Reported nosebleeds and small visible vessel dilations on skin (telangiectasias) within weeks. Lean mass gains were measurable on DXA but functional gains were modest.
▸ Tolerance + cycling deep dive
- Tolerance buildup: Unknown for healthy adults. Theoretically the body could upregulate myostatin or downregulate ActRIIB compensatorily over months. Animal data suggests effect plateaus.
- Recommended cycle: Not applicable — no evidence-based protocol exists.
- Reset protocol: N/A.
▸ Stacking deep dive
Synergistic with
- None evidence-based.
- Theoretical: training load + protein intake (anything that drives hypertrophy stimulus would compound).
Avoid stacking with
- Other anabolic agents (AAS, SARMs, GH, IGF-1, MK-677): Compound cardiac hypertrophy risk, compound tendon-mismatch risk, compound HPG suppression.
- ARBs/ACE inhibitors: Theoretical interaction via shared cardiac remodeling pathways — no human data but caution flag.
Neutral / safe co-administration
- N/A (not recommending the compound, so co-administration question is moot).
▸ Drug interactions deep dive
No documented CYP interactions (it's a glycoprotein, not a small molecule). The relevant interactions are pharmacodynamic: anything affecting the TGF-β superfamily (BMPs, activins, GDFs) or anything affecting cardiac remodeling (RAAS axis drugs, beta blockers).
▸ Pharmacogenomics
- MSTN polymorphisms — rare loss-of-function MSTN variants exist (the German child case); carriers might be hypo-responsive to additional myostatin antagonism (already at floor). Common population variants haven't been mapped to follistatin response.
- ACVR2B polymorphisms — genetic variation in the ActRIIB receptor would theoretically affect response; no commercial test for this on 23andMe.
- 23andMe will not surface relevant SNPs for this compound.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Research-chem peptide | Various ("Peptide Sciences", "Core Peptides", many fly-by-night) | $60-200/vial (1 mg) | Very low | Identity questionable — full-length glycosylated FST cannot be made by standard SPPS peptide synthesis; what's sold is likely a truncated peptide fragment, mislabeled, or inactive. No published independent third-party assays of vendor "follistatin" products confirming identity + bioactivity. |
| Gene therapy (AAV1-FS344) | Trial-only (Nationwide Children's, Sarepta) | N/A | N/A | Not available outside enrollment; one-shot irreversible delivery — unsuitable for biohacking even if available. |
| Recombinant FST for research | Sigma, R&D Systems | ~$300-1000/100 mcg | High (research-grade) | Not for human use, not formulated for injection, identity is real but quantity per dose makes cost prohibitive. |
Bottom line on sourcing: the peptide-vendor "follistatin" market is the most identity-questionable corner of the gray-market peptide world. Even if the vial contains some peptide, it's almost certainly not bioactive intact follistatin glycoprotein. Belief in vendor product = belief in chain-of-custody from a non-existent legitimate manufacturer.
▸ Biomarkers to track (deep)
If, hypothetically, a credible product existed and someone proceeded:
- Baseline (before starting): CBC, CMP, lipid panel, fasting glucose/insulin, testosterone (total + free), LH, FSH, AMH (women) / sperm analysis (men), echocardiogram with LV mass measurement, troponin, creatine kinase, DXA scan.
- During use: Weekly CK + troponin first month; monthly LH/FSH + sex hormones; echo at 12 weeks; DXA at 12 weeks for actual lean mass change vs. baseline (not just scale weight).
- Post-cycle: LH/FSH/AMH/sperm analysis 3 months post for axis recovery; echo for LV mass regression.
▸ Controversies / open debates Live debate
- Is vendor-sourced "follistatin" even bioactive? Strong skepticism. Full-length glycosylated FST-315 or FST-344 is a 30+ kDa post-translationally-modified protein that cannot be made by standard solid-phase peptide synthesis. What's actually in vendor vials is unknown — possibly truncated peptide fragments lacking the heparin-binding domain, possibly mislabeled GHRP/IGF-LR3, possibly inert. No published vendor-product mass-spec assay confirming identity. This is the biggest open question and the one that most pushes toward SKIP for biohacking.
- Does the Acceleron failure generalize? ACE-031 (broad ActRIIB decoy) and ACE-083 (localized FST-Fc fusion) both failed but for different reasons. ACE-031 failed on safety; ACE-083 failed on efficacy translation. Whether full-length systemic follistatin would do better is an open question — but the absence of any company pursuing it suggests insiders don't believe so.
- AAV gene therapy is the only credible delivery path — but that's a one-shot, not-reversible commitment that's clinically inappropriate for healthy adults with no disease indication.
- Cardiac hypertrophy: theoretical or real? Animal data is concerning, human ACE-031 trials weren't long enough or large enough to rule it out, but they also didn't show a strong signal. Equipoise here, which for an elective compound = "skip until proven safe."
▸ Verdict change log
- 2026-05-05 — Initial verdict: SKIP-AT-20 MEDIUM confidence. Animal data is impressive but clinical translation has been a graveyard. Peptide vendor identity is the dealbreaker for biohacking even if other concerns were resolvable. Cross-linked to igf-1 and mk-677 as the comparable "anabolic peptide gray-market" cluster — all three share the "real signal, bad sourcing, downstream priority for users in this archetype" pattern, but follistatin is the worst of the three on identity-verification.
▸ Open questions / gaps Open
- Vendor product mass-spec data — would a third-party lab confirming identity of common vendor "FST-344" products change the calculus? It might, but only enough to move from "definitely-skip" to "skip-but-possible-with-bloodwork-protocol." Cardiac and reproductive concerns remain.
- Gene-therapy long-term follow-up — Mendell IBM cohort 5-10 years out. Any cardiac events? Any tumors? (TGF-β family blockade has theoretical cancer-promotion risk.)
- Bimagrumab post-mortem — why did Novartis kill the program despite Phase 2 lean-mass + fat-loss signal? Unpublished safety signals would be informative.
- Real efficacy ceiling in trained athletes — all clinical trials were in muscle-wasting populations. Healthy trained adults are likely at much smaller delta from genetic ceiling and might gain very little. Bimagrumab obesity data is the closest proxy and was modest.
References
Campbell et al. 2017 — ACE-031 program halt (Muscle Nerve)
safety termination details
View StudyRodgers & Garikipati 2008 — myostatin/follistatin biology (Endocr Rev)
foundational mechanism
View StudyMendell et al. 2017 — AAV1-FS344 in IBM (Mol Ther)
30221-8) — gene therapy safety in inclusion body myositis
View SourceStatland et al. 2020 — ACE-083 FSHD Phase 2 (Neurology)
efficacy miss in FSHD
View SourceLach-Trifilieff et al. 2014 — bimagrumab muscle effects (Mol Cell Biol)
closest analog mechanism + effect size
View SourceAcceleron 8-K filings 2013-2020
public company disclosures of program halts
View SourcePPInteractions8 compounds▸
| Peptide | Status | Note |
|---|---|---|
IGF-1 LR3 | Unknown | Both promote muscle growth through different pathways. Theoretical synergy but no studies on combination. Increased anabolic signaling may compound risks. |
BPC-157 | Unknown | Different mechanisms - BPC-157 promotes tissue repair while follistatin inhibits growth suppressors. No interaction data available. |
TB-500 | Unknown | Both involved in tissue regeneration through different pathways. No published studies on combination effects. |
CJC-1295 | Unknown | Some protocols combine follistatin with GH secretagogues. Different mechanisms but no safety data on combinations. |
HGH | Monitor Combination | Both promote anabolic effects. Theoretical additive muscle growth but combined use increases risk of excessive growth factor stimulation. No clinical data. |
Testosterone/Androgens | Monitor Combination | Androgens increase muscle mass through androgen receptors while follistatin inhibits myostatin. Combined use studied in some animal models but human data lacking. |
ACE-031 | Avoid Combination | Both target myostatin pathway. ACE-031 was discontinued due to vascular side effects. Combining myostatin inhibitors may increase adverse event risk. |
Other Myostatin Inhibitors | Avoid Combination | Stacking multiple myostatin inhibitors provides no proven benefit and may increase risk of off-target TGF-β pathway disruption. |
PP Community insights — click to load ▸
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.